(ASX:BGT) Investor Presentation October 2018
The Global Problem of Pest Control The Ag-Chem industry is seeking new & safer Pest Environmental chemistry as global resistance Resistance Impact continues to worsen Pests are rapidly Public outrage at incumbent developing resistance to products’ toxic impact on bees current insecticides & other beneficial insects Crop Grain Vector-borne Consumer Losses Losses Diseases Products Insects destroy up to 26% Storage pests can cause Cause 17% of global illness Consumers are of global crop production, 25% - 70% loss in stored & disability eg Malaria, demanding natural grain 2 Dengue fever & Zika virus 3 reducing food availability, insecticide products & increasing cost 1 2 1 The Journal of Agricultural Science, Cambridge 2006, 2 Australian Grain Industry & Millennium Development, 2007 3 World Health Organization, 2015
In recent years the problem has worsened Increasing number of resistant species New insecticides are increasingly elusive 700 160,000 Species Resistant Molecules Screened 586 insect species now >140,000 molecules must 140,000 600 resistant to at least one be screened to discover a insecticide class new compound 120,000 500 100,000 400 80,000 300 60,000 200 40,000 100 20,000 0 0 1930 1940 1950 1960 1970 1980 1990 2000 2010 2014 1950 1960 1970 1980 1990 2000 2010 3
New compounds must demonstrate multiple qualities Safe Novel Mode Efficacy Scalability Chemistry of Action New ‘ soft chemistries‘ Compound must Compounds must Technology must be effective, are required, have a novel Mode be able to be which don’t either alone or of Action (MoA) produced at a in combination adversely impact to existing commercial cost with incumbent the environment chemistries to and volume insecticides, or beneficial be effective in in controlling insects (e.g. bees) controlling pests resistant pests 4
Bio- Gene’s technology addresses these needs Safe Novel Mode Efficacy Scalability Chemistry of Action Data shows Flavocide™ Bio- Gene’s compounds Trials show relatively CSIRO collaboration & Qcide™ are highly low toxicity to operate via a has refined effective for controlling bees & other novel Mode of Action, production to be resistant pests across: beneficial insects which addresses commercially viable pest resistance 1) Crop Protection Tox studies to date & Grain Storage indicate no 2) Public Health observable adverse effects to mammals 3) Consumer Products 5
Bio-Gene has two unique compounds Qcide™ Flavocide™ Natural Compound Nature Identical Compound Extract of an A chemical process is Australian eucalypt: used to produce a ‘Gypmie Messmate’ ‘synthetic copy’ of the compound that can be Qcide™ is well suited mass produced to applications in consumer products, Well suited for broad along with public & larger verticals: health & crop protection where a 1) Crop Protection natural product is 2) Public Health preferred 6
Well-defined pathway to commercialisation Testing & Data Generation Create suite of trial data & IP relating to efficacy, toxicity, mode of action Well and manufacturing Progressed Introductory Commercial Discussions Globally Present Bio-Gene to major Ag- Chem, Government Agencies, NGO’s & Underway Philanthropic Organisations Evaluation Partnerships Establish evaluation partnerships, to determine specific market Imminent applications Commercial Deals Progress evaluation partnerships to a commercial deal Future 7
Bio-Gene has delivered on multiple milestones in 2018 Significant Suite of Trial Data Toxicology Studies to Multiple Partnership for Proof of Concept Support Registration Discussions Efficacy Testing Expanded Knowledge Strengthened Improved Appointed Expert of Mode of Action Intellectual Manufacturing Advisors Property Capability 8
Trial Data for Proof of Concept Efficacy Testing Objective Demonstrate effectiveness against pests that are resistant to other classes of chemistry Create suite of testing data across key verticals, to de-risk technology, & support discussions with major Ag-Chem businesses Results achieved in 2018 to date ✓ Overwhelmingly positive results across the key verticals • Proof of control of resistant pests • Control of pests resistant to major chemical groups • Control of major global pest groups Data shows low toxicity to bees & other beneficial insects Next Steps Enhance data set through evaluation partnerships for specific pest focussed testing programs 9
Toxicology Studies to Support Registration Objective Demonstrate the safety of the technology & fulfil registration requirements Achieved in 2018 ✓ Continued formal toxicology & environmental safety studies with accredited third parties to perform necessary testing: • 28- day Oral & Dermal Tox Studies completed for Flavocide™ • Tox- studies commencing for Qcide™ Next Steps Design next level of tox studies to progress towards registration 10
Multiple Partnership Discussions Objective Identify appropriate partners for product evaluation & development Achieved in 2018 ✓ Held multiple meetings in Australia, Europe, US & Asia, with Major Ag-Chem Producers, Government agencies & Not-for-Profit Organisations, covering all key verticals Continued strong interest in our technology Next Steps Establish evaluation partnerships with strategic partners, optimising & testing Qcide™ or Flavocide™ in combination with existing products 11
Expanded Knowledge of Mode of Action Objective Clarify the specifics of the Mode of Action (“MoA”) to apply for a new class of chemistry via IRAC & support IP portfolio Achieved in 2018 ✓ • MoA confirmed via electrophysiological testing by world-class group • Supported by multiple efficacy test data against different resistant pests Next Steps Additional testing underway to elucidate specific sites of activity within the MoA From these results, develop a peer-review paper for submission to the Insect Resistance Action Committee for new class of chemistry 12
Strengthened Intellectual Property Objective Generate data to support current & future patent filings & Intellectual Property Achieved in 2018 ✓ Two additional patent applications lodged Significant manufacturing Intellectual Property Next Steps Continue to identify opportunities to develop Intellectual Property, & implement appropriate data generating studies 13
Improved Manufacturing Capability Objective Improve cost & yield of current manufacturing processes for Qcide™ & Flavocide™ Achieved in 2018 ✓ • Partnership with CSIRO has delivered substantial improvement in the cost of production of Flavocide™ with improved purity and yield • Partnership with James Cook University underway to improve tree oil production & extraction of Qcide™ from production trees Next Steps • Pilot plant trials to scale up production of Flavocide™ • Implement development plans for tree cloning & oil extraction 14
Appointed Expert Advisors Objective Engage specialists in related fields to assess data & assist with next stage testing PROF. CATHERINE HILL NEIL ANDERSON DOUG RATHBONE Purdue University Chemistry & Advisor to the BGT Board Manufacturing Consultant BGT Scientific Advisory Board Member ✓ • >40 years experience in • Purdue University, Dept. of • Industrial Chemist, employed by Monsanto 40 years agriculture. Entomology • MD of Nufarm for >15 years • Showalter Faculty Scholar • Specialist in formulation development, production, & during which Nufarm became • President’s Fellow for the Life one of Australia’s most process management Sciences successful agricultural firms • Qualified for manufacturing plant • Authority in new insecticide with global sales >$2.5B audits, quality & environmental development & novel chemistry management Next Steps • Continue to leverage knowledge of advisory Board • Identify & appoint further experts whose knowledge aligns with commercialisation plans 15
Q&A *Click links to launch Articles 16
Financial Overview Strong Cash Position $0.30 2 Volume (m) BGT has a well funded balance sheet with ~$6.7m in cash (as at end FY18), $0.20 providing a ~2 year runway 1 $0.10 Capital Structure & Financials Shares on Issue 128m $- 0 Nov-17 Feb-18 May-18 Aug-18 $0.13 Share Price (Oct-18) Volume Share Price Options Exercise $0.10 – $0.28 12-month Range Expiry Issued Price 2,000,000 20c 24/11/2020 Market Cap $16.6m Broker Options Options* 25,056,730 20c 4/12/2018 Cash Balance (Jun-18) $6.7m * Options were issued to all shareholders on a 1:5 basis pursuant to Prospectus dated 1/03/2018 17
Recommend
More recommend
